Transdermal Patch: Clinical Trials

18 trials of Transdermal Patch, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 3 recruiting, 2 terminated. 18 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 118Completed 13, Recruiting 3, Terminated 2
Phase 24Recruiting 3, Completed 1

Follow Transdermal Patch: new trials by email Literature Review of Transdermal Patch trials Research Report on Transdermal Patch

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Valproate for the Treatment of Residual Amblyopia
Valproate, Placebo, Patch - Amblyopia, Amblyopia Unilateral
Phase 1 / Phase 2RecruitingBoston Children's Hospital282026-07-012026-07-30
Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting
Lignocaine-loaded maltose microneedle array patch, EMLA 5% patch - Glaucoma, Cataract
Phase 1 / Phase 2RecruitingUniversiti Kebangsaan Malaysia Medical Centre1542025-02-172025-07-18
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
Microneedle Array Doxorubicin (MNA-D) - Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma
Phase 1 / Phase 2RecruitingFalo, Louis, MD482023-09-132026-04-09
Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches
ZTlido (Lidocaine Topical System) 1.8%, Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%) - Healthy
Phase 1CompletedScilex Pharmaceuticals, Inc.242021-07-012021-11-03
A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women
EVRA patch (NGMN+EE) (Treatment A) (Reference), High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test) - Healthy
Phase 1CompletedJanssen Research & Development, LLC682019-07-122025-04-27
Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects
AB001, oral capsule, positive comparative patch - Chronic Low Back Pain
Phase 1CompletedFrontier Biotechnologies Inc.342019-06-242020-03-30
A Study of the Use of Microneedle Patches to Deliver Topical Lidocaine in the Oral Cavity
Microneedle Patch, Patch with no microneedles - Topical Anaesthesia
Phase 1CompletedInnoture Ltd162018-07-312019-11-14
Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase
RIV-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 hours transdermal patch - Bioequivalence
Phase 1CompletedSocraTec R&D GmbH362018-05-162018-08-21
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
Micro needle array-Doxorubicin (MNA-D) - Cutaneous T Cell Lymphoma
Phase 1CompletedFalo, Louis, MD202016-03-092024-08-09
Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects
Lidocaine patch 1.8%, Lidocaine 5% patch, Lidocaine 2% Injectable Solution - Healthy
Phase 1CompletedScilex Pharmaceuticals, Inc.582014-04-282024-05-23
Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches
levonorgestrel - Healthy
Phase 1 / Phase 2CompletedAgile Therapeutics362012-07-012018-01-23
Smoking Termination / Anxiety Reduction Treatment (ST/ART)
Nicotine Patch, Smoking Termination and Anxiety Reduction Treatment, Education-Supportive Psychotherapy - Smoking, Anxiety Disorders
Phase 1CompletedUniversity of Houston742012-03-012019-04-23
Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers
AG200-15 - Healthy
Phase 1CompletedAgile Therapeutics242011-05-012018-07-31
Pharmacokinetic Study of Synera in Healthy Volunteers
Synera - Healthy
Phase 1CompletedZARS Pharma Inc.122010-02-012012-10-17
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch - Turner's Syndrome
Phase 1TerminatedUniversity of Chicago12009-04-012014-03-11
Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations
Patch with centrally acting analgesic, Transtec(R) PRO (buprenorphine) - Healthy
Phase 1TerminatedGrünenthal GmbH242006-10-012016-01-11
Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours
Transtec 35 µg/hour transdermal patch - Pain, Pharmacokinetics
Phase 1CompletedGrünenthal GmbH302004-04-052018-12-10
A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System
Fentanyl 25 μg/h transdermal system, single application, Duragesic 25 μg/h transdermal system single application - Healthy
Phase 1CompletedActavis Inc.482003-06-012010-08-16

Conditions studied

Amblyopia (1)  ·  Anxiety Disorders (1)  ·  Cataract (1)  ·  Eye Diseases (1)  ·  Glaucoma (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Mycosis Fungoides (1)  ·  Pain (1)  ·  Smoking (1)  ·  Turner Syndrome (1)  ·  Vision Disorders (1)

Sponsors

Agile Therapeutics (2)  ·  Falo, Louis, MD (2)  ·  Grünenthal GmbH (2)  ·  Scilex Pharmaceuticals, Inc. (2)  ·  Actavis Inc. (1)  ·  Boston Children's Hospital (1)  ·  Frontier Biotechnologies Inc. (1)  ·  Innoture Ltd (1)  ·  Janssen Research & Development, LLC (1)  ·  SocraTec R&D GmbH (1)  ·  Universiti Kebangsaan Malaysia Medical Centre (1)  ·  University of Chicago (1)  ·  University of Houston (1)  ·  ZARS Pharma Inc. (1)

Countries

United States (8)  ·  Germany (4)  ·  Belgium (1)  ·  Canada (1)  ·  China (1)  ·  Malaysia (1)  ·  Netherlands (1)  ·  United Kingdom (1)

Top investigators

Oleg E Akilov, MD, PhD (2)  ·  Anthony R Godfrey, Pharm.D. (1)  ·  Benoit Girard (1)  ·  Dmitri Lissin, MD (1)  ·  Elizabeth Garner, MD, MPH (1)  ·  Elizabeth Garner, MD, PHD (1)  ·  Eric D Gaier, MD, PhD (1)  ·  Michael J Zvolensky, Ph.D. (1)  ·  Nicola X West (1)

Results publications

PMID 22943969, PMID 32606914, PMID 35696054

NIH funding

2018 (1), 2019 (1), P50CA254865 (1), R34DA031313 (1)